Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications - PubMed (original) (raw)
Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications
H Vlassara et al. Proc Natl Acad Sci U S A. 1992.
Abstract
Advanced glycosylation end products (AGEs) have been implicated in many of the complications of diabetes and normal aging. Markedly elevated vascular tissue and circulating AGEs were linked recently to the accelerated vasculopathy of end-stage diabetic renal disease. To determine the pathogenic role of AGEs in vivo, AGE-modified albumin was administered to healthy nondiabetic rats and rabbits alone or in combination with the AGE-crosslink inhibitor aminoguanidine. Within 2-4 weeks of AGE treatment, the AGE content of aortic tissue samples rose to six times the amount found in controls (P < 0.001). Cotreatment with aminoguanidine limited tissue AGE accumulation to levels two times that of control. AGE administration was associated with a significant increase in vascular permeability, as assessed by 125I label tracer methods. This alteration was absent in animals that received aminoguanidine in addition to AGE. Significant mononuclear cell migratory activity was observed in subendothelial and periarteriolar spaces in various tissues from AGE-treated rats compared to normal cellularity noted in tissues from animals treated with aminoguanidine. Blood pressure studies of AGE-treated rats and rabbits revealed markedly defective vasodilatory responses to acetylcholine and nitroglycerin compared to controls (P < 0.001), consistent with marked NO. inactivation; aminoguanidine treatment significantly prevented this defect. These in vivo data demonstrate directly that AGEs, independent of metabolic or genetic factors, can induce complex vascular alterations resembling those seen in diabetes or aging. AGE administration represents an animal model system for the study of diabetic and aging complications as well as for assessing the efficacy of newly emerging therapies aimed at inhibiting advanced glycosylation.
Similar articles
- Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine.
Li YM, Steffes M, Donnelly T, Liu C, Fuh H, Basgen J, Bucala R, Vlassara H. Li YM, et al. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3902-7. doi: 10.1073/pnas.93.9.3902. Proc Natl Acad Sci U S A. 1996. PMID: 8632987 Free PMC article. - Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats.
Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. Vlassara H, et al. Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11704-8. doi: 10.1073/pnas.91.24.11704. Proc Natl Acad Sci U S A. 1994. PMID: 7972128 Free PMC article. - Advanced glycosylation end products in diabetic renal and vascular disease.
Bucala R, Vlassara H. Bucala R, et al. Am J Kidney Dis. 1995 Dec;26(6):875-88. doi: 10.1016/0272-6386(95)90051-9. Am J Kidney Dis. 1995. PMID: 7503061 Review. - Advanced glycation end products: a Nephrologist's perspective.
Raj DS, Choudhury D, Welbourne TC, Levi M. Raj DS, et al. Am J Kidney Dis. 2000 Mar;35(3):365-80. doi: 10.1016/s0272-6386(00)70189-2. Am J Kidney Dis. 2000. PMID: 10692262 Review.
Cited by
- Non-apoptotic programmed cell deaths in diabetic pulmonary dysfunction: the new side of advanced glycation end products.
Dai Y, Zhou S, Qiao L, Peng Z, Zhao J, Xu D, Wu C, Li M, Zeng X, Wang Q. Dai Y, et al. Front Endocrinol (Lausanne). 2023 Oct 26;14:1126661. doi: 10.3389/fendo.2023.1126661. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37964954 Free PMC article. Review. - Pediatric Type 1 Diabetes: Mechanisms and Impact of Technologies on Comorbidities and Life Expectancy.
Urbano F, Farella I, Brunetti G, Faienza MF. Urbano F, et al. Int J Mol Sci. 2023 Jul 26;24(15):11980. doi: 10.3390/ijms241511980. Int J Mol Sci. 2023. PMID: 37569354 Free PMC article. Review. - Gut microbiota and diabetic kidney diseases: Pathogenesis and therapeutic perspectives.
Lin JR, Wang ZT, Sun JJ, Yang YY, Li XX, Wang XR, Shi Y, Zhu YY, Wang RT, Wang MN, Xie FY, Wei P, Liao ZH. Lin JR, et al. World J Diabetes. 2022 Apr 15;13(4):308-318. doi: 10.4239/wjd.v13.i4.308. World J Diabetes. 2022. PMID: 35582668 Free PMC article. Review. - Antioxidant Potential of Adiponectin and Full PPAR-γ Agonist in Correcting Streptozotocin-Induced Vascular Abnormality in Spontaneously Hypertensive Rats.
Afzal S, Sattar MA, Johns EJ, Eseyin OA, Attiq A. Afzal S, et al. PPAR Res. 2021 Oct 14;2021:6661181. doi: 10.1155/2021/6661181. eCollection 2021. PPAR Res. 2021. PMID: 34691163 Free PMC article. - Experimental Animal Studies Support the Role of Dietary Advanced Glycation End Products in Health and Disease.
Peppa M, Mavroeidi I. Peppa M, et al. Nutrients. 2021 Sep 29;13(10):3467. doi: 10.3390/nu13103467. Nutrients. 2021. PMID: 34684468 Free PMC article. Review.
References
- Science. 1986 Jun 27;232(4758):1629-32 - PubMed
- Proc Natl Acad Sci U S A. 1984 Jan;81(2):583-7 - PubMed
- J Exp Med. 1983 Nov 1;158(5):1739-44 - PubMed
- Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2873-7 - PubMed
- J Clin Invest. 1992 Aug;90(2):439-46 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical